Union MoS for Health and Family Welfare Smt. Anupriya Patel launches 7th National Formulary of India 2026, announces Biovigilance Programme to widen India’s patient-safety net

1. At a Glance

• On 21 September 2026, Union Minister of State for Health & Family Welfare Smt. Anupriya Patel launched the 7th Edition of the National Formulary of India (NFI 2026) along with its digital version, and announced the Biovigilance Programme of India (BvPI). [1]
• The NFI is India's official reference guide for rational, evidence-based prescribing, bridging pharmacopoeial (quality) standards and everyday clinical practice. [3]
• BvPI extends India's existing drug-safety architecture (Pharmacovigilance) to organ/tissue transplantation and biological products, closing a monitoring gap for post-transplant adverse events. [1]
• High UPSC relevance: tests institutional mapping (IPC, CDSCO, AIIMS), evolution of India's "vigilance" ecosystem (Pharmaco-, Materio-, Bio-), and health governance/patient-safety themes for GS-II/III.

2. Why in the News

• Launch event held during the 6th National Pharmacovigilance Week (2026) in New Delhi, where Smt. Anupriya Patel unveiled the 7th NFI and formally announced BvPI. [1]
• Statement by the minister: "patient safety is a top priority of the government." [1]

3. Background & Evolution

• National Formulary of India (NFI): published by the Indian Pharmacopoeia Commission (IPC), with the series regularly updated since 2008. [3]
• Previous edition: the 6th Edition of NFI was launched by then Union Health Minister Dr. Mansukh Mandaviya. [5]
• Pharmacovigilance Programme of India (PvPI): launched July 2010 by CDSCO (Ministry of Health & Family Welfare), with AIIMS New Delhi as initial National Coordinating Centre (NCC) for Adverse Drug Reaction (ADR) monitoring. [4]
• NCC for PvPI shifted to IPC, Ghaziabad, in April 2011, where it remains housed. [4]
• India has since built out a family of "vigilance" schemes — Pharmacovigilance (medicines), Materiovigilance (medical devices), and now Biovigilance (organ/tissue transplantation, biologicals) — all coordinated through IPC. [1]
• The IPC has run annual National Pharmacovigilance Week campaigns to raise ADR-reporting awareness; the 5th edition (September 2025) carried the theme "Your Safety, Just a Click Away: Report to PvPI." [2]

4. Core Static Facts

Item	Detail
Scheme/Document launched	7th Edition, National Formulary of India (NFI 2026) + digital version [1]
New programme announced	Biovigilance Programme of India (BvPI) [1]
Launching authority	MoS Health & Family Welfare, Smt. Anupriya Patel [1]
Parent Ministry	Ministry of Health & Family Welfare (MoHFW) [1][4]
Publishing/Nodal body	Indian Pharmacopoeia Commission (IPC), Ghaziabad — a statutory body under MoHFW [3][4]
Regulatory body (drugs)	Central Drugs Standard Control Organisation (CDSCO) [4]
Original ADR coordinating centre	AIIMS, New Delhi (2010) → shifted to IPC (2011) [4]
Related umbrella event	6th National Pharmacovigilance Week, 2026 [1]
First NFI edition	Series updated regularly since 2008 [3]
BvPI scope	Adverse events from organ/tissue transplantation and biological products [1]

5. Multi-Dimensional Analysis

Social

• Directly affects patient safety and public health outcomes, especially for transplant recipients, a vulnerable and rapidly growing patient category in India. [1]
• Supports informed, evidence-based prescribing by healthcare professionals nationwide via the NFI. [3]

Administrative

• Reflects incremental institution-building: a single nodal agency (IPC) now administers three parallel vigilance verticals (pharmaco-, materio-, bio-), reducing coordination gaps between regulators (CDSCO), academic centres (AIIMS) and the standards body (IPC). [4]
• Success depends on healthcare-provider reporting compliance and last-mile digital reporting infrastructure — a chronic challenge for India's older PvPI framework. [2]

Scientific/Technological

• Digital version of NFI signals push toward e-governance/digital health tools for clinical decision support. [1]
• Biovigilance requires specialized surveillance protocols for transplant biologicals, distinct from small-molecule drug ADR monitoring. [1]

Governance/Ethical

• Institutionalizing organ/tissue transplant safety monitoring addresses accountability gaps in India's growing transplant ecosystem, where donor/recipient safety oversight has historically been weaker than drug safety oversight.
• Continues the government's stated line of "patient safety as a top priority," positioning it within broader universal health coverage and quality-of-care agendas. [1]

Historical

• Extends a lineage of national safety-monitoring programmes: Pharmacovigilance (2010) → Materiovigilance → Biovigilance (2026), each widening the scope of what the state formally monitors for iatrogenic harm. [4][1]

6. Recent Developments (last 12-18 months)

• September 2025: IPC held the 5th National Pharmacovigilance Week, theme "Your Safety, Just a Click Away: Report to PvPI." [2]
• 21 September 2026: 7th NFI (with digital edition) launched; BvPI announced during the 6th National Pharmacovigilance Week. [1]

7. Prelims Hooks

• 7th Edition of the National Formulary of India launched on 21 September 2026. [1]
• Launched by Smt. Anupriya Patel, Union Minister of State (not Cabinet Minister) for Health & Family Welfare. [1]
• National Formulary of India is published by the Indian Pharmacopoeia Commission (IPC), headquartered at Ghaziabad. [3][4]
• NFI series has been regularly updated since 2008. [3]
• The Biovigilance Programme of India (BvPI) was announced alongside the 7th NFI, targeting adverse events in organ/tissue transplantation and biologicals. [1]
• BvPI was announced during the 6th National Pharmacovigilance Week. [1]
• Pharmacovigilance Programme of India (PvPI) was launched in July 2010 by CDSCO. [4]
• PvPI's original National Coordinating Centre was AIIMS, New Delhi; shifted to IPC in April 2011. [4]
• 6th Edition of NFI was earlier launched by Dr. Mansukh Mandaviya (then Union Health Minister). [5]
• India's drug-safety vigilance ecosystem now covers three verticals: Pharmacovigilance (drugs), Materiovigilance (devices), Biovigilance (transplants/biologicals). [1][4]
• CDSCO functions under the Ministry of Health & Family Welfare. [4]
• IPC is a statutory body, not merely an advisory committee. [4]

8. How Many Transplants BvPI Will Have to Watch

• The transplant load has grown about four times in twelve years, with no safety net running alongside it
• India did fewer than 5,000 transplants in 2013. In 2025 it did nearly 20,000 [6].
• All through that growth, adverse events after a transplant had no national reporting system of their own — PvPI covers medicines, not organs [1][4].

• So BvPI is not starting early. It is catching up with a field that already grew large.

• Most organs still come from living donors, and that is a second safety problem

• Only about 18% of transplants use organs from deceased donors [6].
• The rest come from living people — a healthy person who is cut open and loses a kidney or part of a liver.

• Drug safety watches only the patient. Transplant safety has to watch two people: the donor and the recipient. BvPI's announced scope talks about adverse events in transplantation and biologicals [1]; whether the living donor's later health is inside that scope is not yet spelt out.

• The pledge base is big enough that trust is now a policy asset

• More than 4.8 lakh citizens have registered to donate organs after death since 17 September 2023, and over 1,200 families donated a relative's organs in 2025 [6].
• One badly handled infection or cancer passed on through a donated organ, with no system to detect and explain it, can slow that pledging down for years.

9. Why an Organ Is Harder to Track Than a Tablet

• One donor becomes many patients, so one bad organ is many accidents at once
• A single deceased donor can give kidneys, liver, heart, lungs and tissues to several different recipients in different hospitals.
• If that donor carried an undetected infection or cancer, every one of those recipients is at risk together.

• A drug adverse reaction under PvPI is usually one patient at a time. A transplant event is a cluster. Catching it needs the ability to trace every product back to its donor and forward to every recipient, through unique identifier numbers — this traceability is treated as the core of any biovigilance system, not an extra feature [7].

• The harm often appears months later, when nobody is still watching

• Transmitted infection or a donor-origin cancer can show up long after discharge.
• Delayed and less obvious reactions are exactly the ones doctors fail to recognise and record — WHO flags this as the constant weak point of such systems everywhere [7].

• So a reporting form filled at the time of surgery will miss most of what BvPI is meant to find.

• The reporting has to cross institutions, and PvPI never had to

• The organ is retrieved in one hospital and implanted in another.
• The retrieval hospital knows the donor. The transplant hospital knows the outcome. Neither alone can report a full event.
• IPC coordinates the vigilance verticals [1], but the retrieval-and-transplant network itself sits under NOTTO at Safdarjung Hospital [6]. Unless these two are joined by a shared identifier, BvPI will collect half-stories.

10. An Announcement Is Not Yet a Duty to Report

• What was made public on 21 September 2026 is a programme announcement, not a rule
• BvPI was announced during the 6th National Pharmacovigilance Week [1].
• No reporting obligation on hospitals, no defined list of events that must be reported, and no timeline has been placed in the public record alongside it [1].

• WHO's position is that mandatory reporting is what gives a safety system its legal footing and makes sure serious events actually get captured; voluntary reporting is a useful addition on top, not a replacement [7].

• India already knows what voluntary-only looks like

• PvPI has run since July 2010 [4] and still needs an annual awareness week to push doctors to report, with the 2025 theme literally asking them to click and report [2].

• Sixteen years in, the programme is still campaigning for the basic act of reporting. That is the honest baseline BvPI starts from.

• The Formulary has the same soft edge

• The NFI is a reference guide for rational prescribing [3]. A doctor who ignores it breaks no law.
• The digital edition [1] makes it easier to open, which helps. But ease of access is not the same as a reason to change what you already prescribe.

11. What Britain and France Did Differently

• France: reporting is compulsory and every event is put into a fixed set of categories
• France runs a national system where serious adverse events must be reported, using a standard classification [7].
• Fixed categories matter. If two hospitals describe the same harm in different words, the national centre cannot count it as the same thing, and no pattern ever appears.

• BvPI has no published event list or grading scale yet [1].

• UK: reporting is confidential and run by an independent body

• The UK's SHOT scheme collects reports of serious incidents confidentially and sits outside the hospital's own management line [7].
• This directly attacks the real reason doctors stay silent — fear of blame. A protected reporting space is listed by WHO as a core requirement, not a courtesy [7].

• In India, the same body that certifies quality standards also collects the reports: IPC is the statutory standards body and houses the National Coordinating Centre [3][4]. A surgeon reporting a death has to report it to a regulator-linked office.

• Both send the findings back to the people who reported

• WHO lists regular feedback to those who report, plus quick investigation and corrective action, among the essentials [7].
• Without feedback, a busy doctor experiences reporting as unpaid paperwork that vanishes.

12. The Argument That This Is One Vertical Too Many

• The strongest case against BvPI, stated fairly
• India already runs Pharmacovigilance, Materiovigilance and now Biovigilance, all coordinated through IPC [1].
• The oldest of the three, running since 2010, still struggles to get routine reports in [2][4].
• Adding a third vertical on top of a first one that is not yet working can look like building the roof before the walls: more forms for the same overworked hospital staff, and a new programme that exists on paper.

• This objection is partly right. Nothing announced on 21 September 2026 fixes the reporting behaviour that PvPI has struggled with for sixteen years [1][2].

• Why it still does not defeat the case for BvPI

• Transplant harm is not a smaller version of drug harm — it is a different shape. It travels from one donor to several recipients and appears late, so it needs traceability linking donor to recipient, which no amount of fixing PvPI would ever produce [7].
• The volumes are no longer small enough to postpone the question: nearly 20,000 transplants in 2025 [6].
• Sharing one nodal agency is itself a saving. IPC already runs the reporting pipeline and the awareness machinery [1][2][4], so BvPI borrows an existing structure rather than building a parallel one.
• The fair conclusion is not "drop BvPI". It is that BvPI must be given the legal duty and the traceability that PvPI was never given.

13. What Should Happen Next, and Who Must Do It

• MoHFW should make serious transplant events compulsory to report, not optional
• France requires serious adverse events to be reported by law and classifies them in a fixed format [7].
• India's existing programme shows what voluntary-only delivers — annual campaigns still needed to ask doctors to report [2].

• The rule-making power already exists under the Transplantation of Human Organs and Tissues Act, 1994, which governs transplant hospitals; a reporting duty can be attached there rather than waiting for fresh legislation.

• IPC and NOTTO should share one donor identification number

• NOTTO already runs the national network of retrieval and transplant hospitals and tissue banks from Safdarjung Hospital [6]; IPC runs the vigilance reporting [1].
• A single unique identifier carried from the donor to every recipient is what lets one report trigger a check on all the other patients who received organs from that donor [7].

• Without it, BvPI will record isolated events and never see the cluster.

• BvPI should follow patients for years, not days

• Donor-origin infection and cancer surface late, and delayed reactions are the ones most often missed [7].

• So the programme needs scheduled follow-up entries at fixed intervals after surgery, not a one-time form — otherwise the very harms it was created for will not be seen.

• Reports must be protected and answered

• Copy the UK's SHOT model: confidential reporting, handled at arm's length from the body that inspects and certifies [7].
• Send findings back to reporting hospitals on a regular cycle [7]. A doctor who sees a national alert built out of their own report will report the next one.

14. Anchors for Answers

• Data: Transplants in India rose from under 5,000 (2013) to nearly 20,000 (2025); only about 18% use organs from deceased donors [6]
• Data: Over 4.8 lakh citizens registered as organ donors since 17 September 2023; more than 1,200 families donated a relative's organs in 2025 [6]
• Law/Case: Transplantation of Human Organs and Tissues Act, 1994 — the legal backbone BvPI's reporting duty can be attached to
• Comparison: France — legally mandatory reporting of serious events with a fixed classification; UK's SHOT — confidential, independent reporting to remove fear of blame [7]
• Report/Committee: WHO Global Consultation on Haemovigilance — sets traceability from donor to recipient, protected reporting and feedback to reporters as the core requirements of any such system [7]
• Scheme: NOTTO, Safdarjung Hospital, New Delhi — runs the national retrieval-and-transplant network BvPI must be linked to [6]
• Scheme: PvPI (July 2010) — the sixteen-year record that shows what voluntary-only reporting produces [2][4]

15. Mains Relevance

• GS-II: Health — Government policies and interventions for development in health sector; issues relating to development and management of Social Sector/Services relating to Health.
• GS-III: Science & Technology — developments in biotechnology/health-tech applications; also links to issues of governance and regulatory institutions.
• Possible question stems: 1. Discuss the significance of India's expanding 'vigilance' ecosystem (pharmacovigilance, materiovigilance, biovigilance) in strengthening patient safety. What institutional gaps remain? (GS-II) 2. Examine the role of statutory bodies like the Indian Pharmacopoeia Commission in ensuring drug quality and patient safety in India. (GS-II) 3. Organ transplantation is a growing area of Indian healthcare, yet safety monitoring has lagged behind drug safety monitoring. Critically evaluate the need for a dedicated Biovigilance Programme. (GS-II/III)

16. Related Topics to Study Next

• Pharmacovigilance Programme of India (PvPI) — the older, parallel programme BvPI is modeled on.
• Central Drugs Standard Control Organisation (CDSCO) — India's central drug regulator, relevant to all vigilance schemes.
• Indian Pharmacopoeia Commission (IPC) — statutory body now central to India's medicine/device/biologicals safety framework.
• Transplantation of Human Organs and Tissues Act (THOTA), 1994 — legal backbone for organ transplantation regulation in India.
• New Drugs and Clinical Trials Rules, 2019 — regulatory framework for drug approval and monitoring.
• National Health Policy, 2017 — broader policy context for patient-safety and quality-of-care goals.
• Ayushman Bharat / PM-JAY — links healthcare quality and safety to India's flagship health insurance scheme.

17. Common Errors / Trap Areas

• Confusing MoS Anupriya Patel with the Cabinet Minister for Health & Family Welfare — she is Minister of State, not the senior-most minister. [1]
• Mixing up IPC (Indian Pharmacopoeia Commission) with CDSCO — IPC hosts the NCC for PvPI/BvPI and publishes NFI; CDSCO is the drug regulator that initiated PvPI. [4]
• Assuming Biovigilance and Pharmacovigilance are the same — BvPI specifically targets organ/tissue transplantation and biologicals, distinct from ADR monitoring of conventional drugs under PvPI. [1]
• Placing IPC's headquarters incorrectly — it is at Ghaziabad, not New Delhi (though many events/launches occur in New Delhi). [4]
• Misdating the NFI series origin — regularly updated since 2008, not the launch year of any single edition. [3]